Perspective Q3 2026: $202M Cash Into 2028, PSV359 Fast Track, Merck Collaboration
CATX is trading near its 52-week low of $0.781 (10% above the low).
Summary
Perspective ended the third quarter with about $202 million in cash and investments, enough to fund operations into 2028, while reporting a $32.4 million quarterly net loss. The release also disclosed FDA Fast Track status for PSV359 and a Merck supply collaboration for Keytruda combination studies.
Key Events · Earnings and Guidance · CATX
-
Q3 Loss Widens on Higher R&D
Net loss was $32.4 million, or $0.27 per share, versus $26.0 million, or $0.35 per share, a year earlier; R&D rose to $26.1 million from $20.3 million.
-
Cash Runway Extended Into 2028
Cash, cash equivalents and short-term investments totaled approximately $202 million at September 30, 2026, up from approximately $145 million at December 31, 2025.
-
PSV359 Wins FDA Fast Track
In October 2026 the FDA granted Fast Track Designation to PSV359 for adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors.
-
Merck Keytruda Supply Agreement
A September 2026 clinical trial collaboration and supply agreement with Merck supports evaluating PSV359 with Keytruda in certain lung and colorectal cancers.
Analysis · CATX · Life Sciences
Balance sheet durability is the quarter's headline: roughly $202 million in cash and short-term investments at September 30, 2026, which management says funds planned clinical milestones and operations into 2028. That removes near-term financing pressure for a company burning about $34.3 million a quarter in operating expenses, even as the net loss widened to $32.4 million from $26.0 million a year earlier on higher R&D spending. Alongside the numbers, PSV359 picked up FDA Fast Track Designation in October 2026 for FAP-positive solitary fibrous tumors, and a September 2026 clinical collaboration with Merck will supply Keytruda for combination testing in certain lung and colorectal cancers. The lead program, bamzireotide navoxetan, has closed enrollment in Cohort 4 and is targeting an end-of-Phase 2 meeting with the FDA in the first quarter of 2027, the gate to a registrational study.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CATX was trading at $0.86 on NYSE in the Life Sciences sector, with a market capitalization of approximately $97.7M. The 52-week trading range was $0.78 to $6.16. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.